Suzhou Sinovent Pharmaceuticals Co., Ltd.

Hangzhou Minsheng Pharmaceutical Co. Ltd

Hangzhou Rex Pharmaceutical Co., Ltd.

Hangzhou Yuanchang Medical Sci-Tech Co., Ltd

Hangzhou Minsheng Institutes for Pharma Research Co., Ltd

Hangzhou Minsheng Institutes for Pharma Research

Hangzhou Minsheng Pharmaceuticals Co., Ltd.

Ximing Shen

Dong Wang

Yaodong Wu

Yujun Gao

Juan Zhou

Binbin Hong

Yonghui Wang

Chunqi Li

Binnan Huang

Tao Liu

Dianwu Guo

Shulong Wang

Qiufu Ge

Lan Yang

Feiyu Feng

Wandeng Liu

Jian Cai

Zhenhua Liu

Zhonghua Peng

Shiqun Wang

Jiaqi Shan

Yan Zhu

Chunxia Wu

A five-membered heterocyclic amide WNT pathway inhibitor having the following general structural formula: The five-membered heterocyclic amide WNT pathway inhibitor has a remarkable anti-tumor activity based on a target-based rational drug design, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

Five-membered heterocyclic amides WNT pathway inhibitor

The present invention discloses a compound for regulating protein kinase activity and used for treating or preventing diseases associated with protein kinases. Specifically, the present invention relates to a benzofuran pyrazole amine protein kinase inhibitor which belongs to compounds that regulate anaplastic lymphoma kinase (ALK), and provides a method of preparing such a compound and a pharmaceutical use of such a compound in the treatment or prevention of diseases associated with ALK. The inhibitor can solve the problem of the drug resistance of the first generation and the second generation of ALK inhibitors.

Benzofuran pyrazole amine kinase inhibitor

The invention provides gemcitabine derivatives shown in the following formula (I) and preparation methods thereof. The invention further relates to a pharmaceutical composition which comprising the said gemcitabine derivatives in an effective amount and a pharmaceutically acceptable excipient or additive. The invention further provides use of the said derivatives for preparing anti-tumor drugs. The compound designed by the invention is novel in structure and has a remarkable anti-tumor activity. According to the compound designed by the invention, the preparation starting materials have extensive sources and are easily obtained, the preparation method is simple and easy to operate, and the yield of the product is high, so that industrial production on a large scale is facilitated. 

Gemcitabine derivatives, compositions comprising same and pharmaceutical applications thereof

A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.

Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament

Growing community of inventors

Zhejiang, China

Ximing Shen